Credits: Unsplash
A report by Swachh Bharat Mission says that 74.5 per cent of public places are equipped with toilets. Another report by the Ministry of Jal Shakti states that there are 2.23 lakh Community Sanitary Complexes built across all States and UTs under the Swachh Bharat Mission (SBM) since October 2014. Over 92 lakh toilets have been constructed since the launch of SBM Gramin (SBM (G)) in April 2020.
While toilets are there, are they accessible? This is the question one should ask. The National Family Health Survey (NFHS) focuses on 131 health indicators, but not until the NFHS 5 survey did they include the question of accessibility of toilets in the survey. This happened after the inputs from the Department of Drinking Water and Sanitation (DDWS) and the Ministry of Health & Family Welfare questioned the accessibility.
One might ask, why is the question of accessibility so important? The answer is quite simple. Access to water, sanitation and hygiene is the most basic human need and is also included under the Sustainable Development Goals by the UN.
This thought crossed my mind because back in 2021, I went on a solo trip, on a bus to Udaipur from Delhi. There, the bus made two stoppages. This was done so people could get a quick dinner and freshen up, relieve themselves and be prepared for the rest of the journey. This was a nightmare. The bus only stopped for 10 minutes. While some men used the washroom, others went to the bushes.
For the women, there were three cubicles. One of them was broken, and the other one did not have a light bulb, which meant only one was usable. There was a long queue for that cubicle, and time was short. There was no point in trying to find an isolated corner, because it was past midnight, in an unknown area.
I waited anxiously. When finally, my turn came, I saw an overused, dirty washroom. The toilet seat is in a horrible condition. I wanted to touch nothing there. But I had to pee. So, I used my mask to cover my nose from the odour, folded my pants so they did not touch the floor and squatted. It was quite a task to balance.
On my way back to Delhi, I made sure to not drink any water for over a 13-hour bus journey. I dehydrated myself so I did not have to use the washroom. When I did reach, I was severely dehydrated and was sick for three days.
I shared my experience with my friends only to realise that many women have faced the same. There are no washrooms for women.
A friend of mine told me that it is because these roads and dhabas are mainly designed to serve men. They are the ones who travel at night or are on the roads most of the time. As a result, the few women who do travel or are on the road suffer.
Well, it is true, but partially. While holding your pee for too long can lead to health risks, peeing on a dirty toilet seat cannot lead to infections unless your urethra is in contact with the bacteria present on that toilet seat. However, nobody wants to sit on a dirty toilet seat, even if you do not get an infection. A safe and hygienic toilet is a basic need.
One of the regular saleswomen, Usha, who visits my house shared her experience with me. “Being on the road constantly means I must use the dirty public washrooms. But I do not want to use them. So, sometimes I ask my regular customers to let me use their washrooms. Some say yes, and some say no. I understand they are also concerned about their safety and privacy,” she says. As a result, Usha spends most of her day not drinking enough water and holding her pee when she is at work. Due to this, she also suffered from a Urinary Tract Infection (UTI).
Her friend, Halima too faced similar problems and due to increased levels of uric acid in her body, she suffered from Hyperuricemia.
Other health risks are kidney stones and other kidney problems, headaches, dull skin, xerostomia or dry mouth, fatigue, and urinary incontinence, which means losing control over your pelvic floor muscles leading to uncontrolled leakage of urine, seizures and weakness.
Wear comfortable clothes and capris. Capri pants are comfortable and are short in length, which means this won’t touch the toilet floor when you squat or sit.
Even though you cannot get a UTI alone from sitting on a toilet seat, it is always safe to carry a toilet seat sanitiser. If nothing, it can help you get rid of the bad odour so you can use your stand and pee device inside the toilet. You can also use disposable toilet seat covers if your knees are weak, and you cannot squat. Always flush with your seat down.
Always keep disposable gloves, a portable bidet (fill it with water before use), a pocket liquid handwash, wet wipes, tissues and sanitiser handy. Do not forget to keep extra sanitary pads. It might sound a lot, but I promise that it all fits in one pouch. Use this travel-friendly pouch every time you are on the road, or using a public washroom.
However, in case we do not get these technologically advanced toilets here, you can always pack a travel-friendly toilet kit!
Credit: iStock
Hepatitis remains one of the most misunderstood liver conditions, largely because it isn't a single disease but a group of infections—A, B, C, D, and E—each of which behaves very differently once it enters the body.
The question "can hepatitis be cured?" doesn't have one straightforward answer. The truth lies somewhere between full recovery and lifelong management, depending entirely on which type of hepatitis a person has contracted.
Hepatitis A and E are generally short-lived infections. The liver, in most cases, clears these viruses naturally without any specific antiviral medication. Rest, hydration, a balanced diet, and avoiding alcohol are usually enough to help the body recover fully. Chronic infection is rare with these two types, and when it does occur, particularly with Hepatitis E in people with weakened immunity, it can still be treated successfully.
Hepatitis C tells a much more encouraging story. Thanks to advances in medicine, Direct-Acting Antivirals, or DAAs, now cure more than 95 percent of cases. These are oral tablets taken for roughly eight to twelve weeks, and they carry minimal side effects compared to older treatments. For patients diagnosed early, Hepatitis C is, quite genuinely, curable.
Hepatitis B and D are a different story altogether. When the infection is acute, the body often fights it off on its own without much trouble.
Chronic cases, though, are far tougher to deal with. As of now, no medication can fully remove the Hepatitis B virus from the body once it settles in. What doctors can do is keep it under control, usually through antiviral tablets or interferon injections, so that it doesn't quietly damage the liver over time and lead to cirrhosis or cancer. For many patients, this isn't a short course of treatment. It's something they may need to stay on for years, and in several cases, for the rest of their lives.
Hepatitis D is considered the more severe of the two, and it only shows up in people who already have Hepatitis B; it cannot infect someone on its own. Treatment choices here are still quite limited. A few newer drugs have shown some promise in keeping the disease in check, but nothing yet counts as an actual cure. When the liver damage has progressed too far, a transplant sometimes becomes the only way forward.
The single most important factor in determining outcomes across all types of hepatitis is timing. Detected early, Hepatitis C can be eliminated. Detected early, Hepatitis B can be controlled well enough that liver damage never progresses. Left unchecked, however, both can silently damage liver tissue for years before symptoms even appear.
Regular liver function tests, hepatitis screening for those at risk, and vaccination—especially for Hepatitis B—remain the strongest tools available for prevention and timely intervention.
Hepatitis doesn't follow a single script, and that's something patients often find confusing at first. Some forms clear up completely with the right treatment, others require ongoing management to keep the virus in check, and in many cases, vaccination and timely screening make the real difference in avoiding complications down the line.
Knowing exactly which type of hepatitis one is dealing with is what allows a doctor and patient to set realistic expectations and work out a treatment plan that actually fits the situation.
Credit: AI
The rise of GLP-1 medications such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide) has transformed obesity and diabetes treatment.
However, soaring demand and earlier drug shortages also fueled the rapid growth of compounded GLP-1 drugs, which are now under increasing scrutiny from regulators and medical experts.
Over the past few months, the U.S. Food and Drug Administration (FDA) has intensified its crackdown on compounded GLP-1 products, warning that patients could face quality, dosing, and safety concerns if they obtain these medications from unlawful sources.
A compounded drug is a medication that is custom-made by a licensed compounding pharmacy to meet an individual patient's specific medical needs. For example, removing an allergen, changing the dosage, or preparing a formulation that is not commercially available.
The FDA said, "Compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed."
Also read: People Are Microdosing GLP-1 Weight Loss Drugs; What Do Experts Have To Say About It?
Demand for GLP-1 medications for weight loss skyrocketed worldwide between 2022 and 2025, leading to shortages of semaglutide and tirzepatide.
During these shortages, compounding pharmacies were legally allowed under specific circumstances to prepare several versions of these medications.
Many patients turned to compounded GLP-1s because they were often affordable, available, and easier to buy online.
Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real
FDA's efforts to restrict this practice include widespread compounding of semaglutide, tirzepatide, and liraglutide.
The agency has proposed excluding these drugs from the list of bulk substances used for large-scale compounding because FDA-approved alternatives are now available.
It has also issued warning letters to companies producing compounded GLP-1 products outside permitted circumstances.
Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?
A new University of Colorado Anschutz Medical Campus secret shopper study published in July 2026 found that the compounded GLP-1 market remains active even after shortages have been curbed.
Researchers reported that many online pharmacies were still selling compounded semaglutide or tirzepatide, with some products originating from pharmacies lacking compounding licenses.
Small differences in concentration may result in patients receiving too much or too little medication.
Injectable medicines must be manufactured under strict sterile conditions. Improper preparation increases the risk of contamination.
Some compounded products have reportedly used semaglutide salts or added vitamins and other substances that are not present in FDA-approved versions. The FDA has previously stated that certain semaglutide salt forms have not been demonstrated to be safe or effective.
Because compounded products are not FDA-approved, they have not undergone the rigorous clinical trials evaluating effectiveness, manufacturing consistency, and long-term safety.
Experts warn that some websites advertise compounded GLP-1 medications that may not come from legitimate pharmacies at all.
Credit: AI
As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.
Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.
However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.
Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.
HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.
Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."
Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real
Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.
The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."
These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.
Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.
Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.
Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?
Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.
Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."
Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.
Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."
Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So
Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.
The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."
© 2024 Bennett, Coleman & Company Limited